PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Attomey's Docket No. 13407-020001

Application No. 10/656,530

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Applicant DiStefano et al.

Filing Date September 5, 2003

Group Art Unit 1639

Substitute Disclosure Form (PTO-1449)

(37 CFR §1.98(b))

			U.S. Pate	ent Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
SL	AA	4,224,199	09/23/1980	Meyers et al.			
	AB	5,770,687	06/23/1998	Hornik et al.			
	AC	5,811,392	09/22/1998	Gilon et al.			
	AD	5,929,040	07/27/1999	Werther et al.			
	AE	5,942,489	08/24/1999	Schally et al.			
	AF	5,962,409	10/05/1999	Deghenghi			
	AG	5,981,533	11/09/1999	Traxler et al.			
	AH	6,057,422	05/02/2000	Schally et al.			
	AI	6,180,636	01/30/2001	Traxler et al.		V	
	AJ	6,242,199	06/05/2001	Pai et al.		\wedge	
	AK	6,251,865	06/26/2001	Clark et al.			
	AL	6,284,741	09/04/2001	Werther et al.			
	AM	6,337,338	01/08/2002	Kozlowski et al.			
	AN	6,395,733	05/28/2002	Lee et al.			
	AO	20030087806	05/08/2003	Danko et al.			
	AP	6,573,293	06/03/2003	Tang et al.			
-V	AQ	20050201938	09/15/2005	Bryant et al.			

	Foreia	n Patent Doo	cuments or P	ublished Foreign	Patent A	Application	ns	
Examiner Initial	Desig.	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
SL	AR	WO 02/072780	09/19/2002	WIPO				/
	AS	WO 02/102804	12/27/2002	WIPO				
	AT	WO 02/102805	12/27/2002	WIPO				
	AU	WO 03/000688	01/03/2003	WIPO				
	AV	EP 1 284 144	02/19/2003	Europe				
V	AW	WO 03/018021	03/06/2003	WIPO				

Examiner Signature	/Sue Liu/	Date Considered	12/04/2006	
EXAMINER: Initials cita	tion considered. Draw line through citation	if not in conformance and not o	considered. Include copy of this form with	

next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 13407-020001	Application No. 10/656,530		
Information Disclosure Statement by Applicant		Applicant DiStefano et al.			
1	(Use several sheets if necessary)		Group Art Unit		
(37 CFR §1.98(b))		September 5, 2003	1639		

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass		lation No
SL	AX	WO 03/018022	03/06/2003	WIPO				

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
SL	AY	Baldelli et al., "Growth hormone secretagogues as diagnostic tools in disease states," Endocrine, 14(1):95-9, February 2001.
	AZ	Bartke et al., "Extending the lifespan of long-lived mice," Nature 414(6862):412, November 22, 2001.
-:	AAA	Bartke and Clancy, "Dietary restriction and life-span," Science 296:2141-42, June 21, 2002.
	ABB	Bartke et al. "Genes that prolong life: relationships of growth hormone and growth to aging and life span," J. Gerontol. Biol. Sci. 56(8):B340-9, August 2001.
	ACC	Blum et al. "Substrate competitive inhibitors of IGF-1 receptor kinase," Biochemistry 39(51):15705-12, December 26, 2000.
	ADD	Carter et al., "A critical analysis of the role of growth hormone and IGF-1 in aging and lifespan," TRENDS in Genetics, 18(6):295-301, June 2002.
	AEE	Culler et al. "Somatostatin receptor subtypes: targeting functional and therapeutic specificity," Ann. Endocrinol. (Paris) 63(2 Pt 3):2S5-12, April 2002.
	AFF	Deghengi et al., "Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland," Endocrine, 14(1):29-33, February 2001.
	AGG	DiMartino et al. "The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver," Blood 98(3):618-626, August 1, 2001.
	АНН	Flurkey et al., "Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production," Proc. Natl. Acad. Sci. U S A. 98(12):6736-41, June 5, 2001.
	AII	Garcia de la Torre et al., "Antiangiogenic effects of somatostatin analogues," Clin. Endocrinol. 57:425-441, 2002.
	AJJ	Garcia et al., "PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression," Mol. Endocrinol. 16(2):342-52, February 2002.
	AKK	Ghigo et al., "Hypothalamic growth hormone-insulin-like growth factor-I axis across the human life span," J. Pediatr. Endocrinol. Metab. 13 Suppl 6:1493-502, 2000.
	ALL	Hailey et al., "Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells," Mol. Cancer Ther. 1(14):1349-53, December 2002.
	AMM	Hintz et al. "Prediabetic insulin resistance is not permissive to the development of cardiac resistance to insulin-like growth factor I in ventricular myocytes," Diabetes Res. Clin. Pract. 55(2):89-98, February 2002.
V	ANN	Holzenberger et al., "IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice," Nature 421(6919):182-7, January 9, 2003, Epub. December 4, 2002.

Examiner Signature /	Sue Liu/	Date Considered	12/04/2006
EXAMINER: Initials citation consider	ed. Draw line through citation	if not in conformance and not o	considered. Include copy of this form with

next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office			
by Applicant (Use several sheets if necessary)		Applicant DiStefano et al.		
		Filing Date September 5, 2003	Group Art Unit 1645 1639	

	Other Do	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
SL	A00	Melov et al., "Extension of life-span with superoxide dismutase/catalase mimetics," Science 289:1567-69, September 1, 2000.
	APP	Miller et al., "Gene expression patterns in calorically restricted mice: partial overlap with long-lived mutant mice," Mol. Endocrinol. 16(11):2657-66, November 2002.
	AQQ	Morris et al., "A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans," Nature 382(6591):536-9, August 8, 1996.
	ARR	Nargund et al., "Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential," J. Med. Chem. 41(17):3103-27, August 13, 1998.
	ASS	Orrego et al., "Semiquantification of hypothalamic GH-releasing hormone output in women: evidence for sexual dimorphism in the mechanism of the somatopause," J. Clin. Endocrinol. Metab. 86(11):5485-90, November 2001.
	ATT	Pasternak et al. "Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization," Bioorg. Med. Chem. Lett. 9(3):491-6, February 8, 1999.
	AUU	Patchett et al. "Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue," Proc. Natl. Acad. Sci. U S A. 92(15):7001-5, July 18, 1995.
	AVV	Root and Root "Clinical pharmacology of human growth hormone and its secretagogues," Curr. Drug Targets Immune Endocr. Metabol. Disord. 2(1):27-52, April 2002.
	AWW	Saeki et al., "Insulin-like growth factor-1 protects peroxynitrite-induced cell death by preventing cytochrome c-induced caspase-3 activation," J. Cell Biochem. 84(4):708-16, 2002.
	AXX	Sato et al. "Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)," Oncogene 21(11):1727-38, March 7, 2002.
	AYY	Schally et al., "Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents," Trends Endocrinol. Metab. 10(10):383-391, December 1999.
	AZZ	Shimokawa et al., "Life span extension by reduction in Growth Hormone-Insulin-Like Growth Factor-1 axis in a transgenic rat model," Am. J. Pathol. 160(6):2259-65, June 2002.
	AAAA	Swanson et al., "The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis," Carcinogenesis 23(6):977-82, June 2002.
	ABBB	Swerdlow et al., "Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study," Lancet 360:273-77, July 27, 2002.
	ACCC	Wen et al. "Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells," Br. J. Cancer 85(12):2017-21, December 14, 2001.
	ADDD	Yang et al. "Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2," Proc. Natl. Acad. Sci. U S A 95(18):10836-41, September 1, 1998.
V	AEEE	Zarandi et al., "Synthesis and biological activities of highly potent antagonists of growth hormone- releasing hormone," Proc. Natl. Acad. Sci. U S A 91(25):12298-302, December 6, 1994.

Examiner Signature	/Sue Liu/	Date Considered	12/04/2006
EXAMINER: Initials citation next communication to ap	on considered. Draw line through cit plicant.	ation if not in conformance and not o	considered. Include copy of this form with

Substitute Disclosure Form (PTO-1449)

Substitute-Eorm PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 13407-020001	Application No. 10/656,530	
Information Disclosure Statement by Applicant Statement by Applicant statement		Applicant DiStefano et al.		
Use several st	neets if necessary)	Filing Date September 5, 2003	Group Art Unit 1639	

O TRAVE			U.S. Patent	Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA		·				
	Ab						
	AC			·			
	AD						
	AE						
	AF			·			
	AC						
	AH						

Foreign Patent Documents or Published Foreign Patent Applications									
Examiner Initial	Desig.	Document Number	Publication Date	Country or Patent Office	Class	Subclass		lation No	
Illilidi	AI	Number	Date	T atom Omice	0.033	Gaboiago	100		
	AJ								
	AK								

Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
SL	AL	Kopchick and Okada, "Growth hormone receptor antagonists: discovery and potential uses," Growth Hormone & IGF Res., Supplement A, S103-S109, 2001.			
*****************	AM				
	AN				
	AO				

Examiner Signature /Sue Liu/	Date Considered
, 200 ===,	12/04/2006
EXAMINER: Initials citation considered. Draw line through cit	tation if not in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Disclosure Form (PTO-1449)